Ligand Pharmaceuticals Inc. (LGND) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Ligand Pharmaceuticals is a biopharmaceutical royalty company focused on acquiring and creating diversified royalty streams from high-value medicines. The company operates a single segment, investing in clinical development and commercialization of medicines. A significant subsequent event occurred on July 14, 2026, with the completion of the acquisition of XOMA Royalty Corporation, doubling the company's portfolio to over 200 assets.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | YTD 2026 | YTD 2025 |
|---|---|---|
| Total Revenues and Income | $115.4 million | $93.0 million |
| Net Income (Loss) | $35.2 million | ($37.6 million) |
| Diluted EPS | $1.63 | ($1.95) |
| Operating Cash Flow | $72.7 million | ($9.6 million) |
| Cash and Short-Term Investments | $1,357.8 million | $733.5 million (Dec 31, 2025) |
| Convertible Senior Notes (Net) | $1,126.6 million | $446.2 million (Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24% year-over-year (YTD), driven by a 42% increase in royalty revenue to $91.0 million. Key contributors included Filspari, Zelsuvmi, Ohtuvayre, Capvaxive, and Kyprolis.
- Profitability Turnaround: The company reported a net income of $35.2 million compared to a net loss of $37.6 million in the prior year. This was driven by a $53.7 million improvement in operating income, largely due to the absence of a $44.3 million R&D funding charge recognized in Q1 2025 (Castle Creek Investment) and continued royalty growth.
- Non-Operating Volatility: Non-operating income was significantly impacted by mark-to-market adjustments. Q2 2026 saw a $35.7 million gain from changes in fair value of equity-method investments (Pelthos), while YTD 2026 reflected a $13.5 million loss in this category. Short-term investment gains were $15.6 million YTD 2026 vs. a $11.4 million loss YTD 2025.
- Capital Structure: In June 2026, the company issued $700.0 million of 0.00% Convertible Senior Notes due 2031. Net proceeds were approximately $679.0 million. Approximately $60.0 million of proceeds were used to repurchase 228,859 shares of common stock.
- Expense Fluctuations: R&D expenses decreased 70% YTD due to the absence of the Castle Creek charge and deconsolidation of the former Pelthos business, partially offset by a $12.3 million funding arrangement with Orchestra BioMed. G&A expenses increased 28% YTD due to transaction costs related to the XOMA Acquisition and higher employee costs.
Guidance, Outlook, and Risks
- Outlook: Management expects the XOMA Acquisition to be immediately accretive. The company plans to continue its capital deployment strategy, investing approximately $150 million to $250 million annually in high-value royalty assets.
- Portfolio Updates:
- Filspari: FDA approved for FSGS; reported $141 million in U.S. net sales in Q2 2026 (96% YoY growth).
- Ohtuvayre: Reported $204 million in net sales in Q2 2026.
- Qtorin Rapamycin: Rolling NDA submission underway; Phase 3 trial planned for Q4 2026.
- Volixibat: Granted Breakthrough Therapy Designation for cholestatic pruritus due to PSC.
- Risks and Contingencies:
- Integration Risk: Risks associated with integrating XOMA Royalty's operations and portfolio.
- Debt Obligations: Ability to service debt depends on future performance; notes may be repurchased upon a "Fundamental Change."
- Legal Proceedings: Ongoing litigation with Viking regarding the TR-Beta Program termination; National Prescription Opiate Litigation (MDL); and a resolved patent dispute with PH Health regarding Nexterone.
- Royalty Buyouts: Licensees may exercise rights to buy out royalty obligations, potentially reducing future revenue.
Investor Verification Checklist
- XOMA Acquisition Integration: Verify the timeline and financial impact of integrating XOMA Royalty's 200+ assets and the associated contingent value rights (CVRs).
- Debt Covenants: Review the amended credit agreement covenants, specifically the minimum consolidated EBITDA requirements ($100M for trailing four quarters ending June 30, 2026, increasing to $150M thereafter).
- Non-Operating Volatility: Assess the sustainability of earnings given the significant impact of mark-to-market adjustments on equity investments (Pelthos) and short-term investments.
- Royalty Concentration: Monitor sales performance of top royalty drivers (Filspari, Ohtuvayre, Capvaxive) and potential patent expirations or buyout exercises by partners.
- Liquidity Position: Confirm the utilization of the $125.0 million revolving credit facility and the deployment of the $679.0 million net proceeds from the 2031 Notes.